Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bisphosphonates in multiple myeloma.

J F Apperley1, P I Croucher

  • 1Department of Haematology, Imperial College School of Medicine, London, England.

Pathologie-Biologie
|April 8, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sequential BCR::ABL1 evaluation during dose de-escalation in peripheral blood is more predictive of TFR success than single assessment at dose de-escalation in either peripheral blood or bone marrow.

Leukemia·2026
Same author

Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy.

British journal of haematology·2024
Same author

Managing women of childbearing age with chronic myeloid leukemia: safety and treatment considerations.

Expert review of hematology·2023
Same author

Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations.

Journal of bone oncology·2021
Same author

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Leukemia·2020
Same author

Corrigendum to "Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells" [Bone 122 (May 2019) 82-92].

Bone·2019
Same journal

Pathologie-biologie·2020
Same journal

Antibacterial and antibiofilm activities of Laurus nobilis L. essential oil against Staphylococcus aureus strains associated with oral infections.

Pathologie-biologie·2015
Same journal

[Not Available].

Pathologie-biologie·2015
Same journal

Oxidative damage and histopathological changes in lung of rat chronically exposed to nicotine alone or associated to ethanol.

Pathologie-biologie·2015
Same journal

Biological diagnosis of diabetes mellitus.

Pathologie-biologie·2015
Same journal

Association of CagPAI integrity with severeness of Helicobacter pylori infection in patients with gastritis.

Pathologie-biologie·2015
See all related articles

Multiple myeloma often causes bone disease. Bisphosphonates show benefit in clinical trials for myeloma patients, though optimal use and effects on the underlying disease require further study.

Area of Science:

  • Oncology
  • Bone Biology
  • Pharmacology

Background:

  • Bone disease is a common and debilitating complication of multiple myeloma.
  • Understanding the interplay between myeloma cells and bone remodeling cells (osteoclasts, osteoblasts) is crucial.

Purpose of the Study:

  • To review mechanisms of bone destruction in multiple myeloma.
  • To discuss the role and efficacy of bisphosphonates in managing myeloma-related bone disease.

Main Methods:

  • Review of current theories on myeloma-induced bone destruction.
  • Analysis of clinical studies, including Phase III randomized controlled trials, on bisphosphonate use in multiple myeloma.

Main Results:

  • Bisphosphonate treatment has generally shown benefit in clinical studies for multiple myeloma bone disease.

Related Experiment Videos

  • Some trials suggest bisphosphonates may impact the underlying myeloma, supported by preliminary laboratory data.

    • Conclusions:

    • Bisphosphonates are beneficial in multiple myeloma bone disease, but optimal treatment strategies are still being defined.
    • Emerging evidence suggests potential anti-myeloma effects of bisphosphonates warrant further investigation.